ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics


ALX Oncology Holdings Inc. (ALXO): $10.61

0.04 (+0.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALXO Stock Price Chart Interactive Chart >

Price chart for ALXO

ALXO Price/Volume Stats

Current price $10.61 52-week high $34.42
Prev. close $10.57 52-week low $5.82
Day low $10.15 Volume 45,202
Day high $10.75 Avg. volume 349,652
50-day MA $11.27 Dividend yield N/A
200-day MA $12.18 Market Cap 432.41M

ALX Oncology Holdings Inc. (ALXO) Company Bio


ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.


ALXO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALXO Latest Social Stream


Loading social stream, please wait...

View Full ALXO Social Stream

Latest ALXO News From Around the Web

Below are the latest news stories about ALX ONCOLOGY HOLDINGS INC that investors may wish to consider to help them evaluate ALXO as an investment opportunity.

ALX Oncology Appoints Scott Garland to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the “Board”) effective November 29, 2022. With more than 30 years of biopharmaceutical industry knowledge, Mr. Garland brings deep commercial and executive leadership experience. “Scott is a biopharm

Yahoo | November 29, 2022

H.C. Wainwright Sticks to Its Buy Rating for ALX Oncology Holdings (ALXO)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ALX Oncology Holdings (ALXO - Research Report) today and set a price target of $65.00. The company's shares closed yesterday at $12.50.According to TipRanks, Ramakanth is an analyst with an average return of -14.7% and a 28.76% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, MiMedx Group, and Rewalk Robotics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ALX Oncology Holdings with a $65.00 average price target.

Christine Brown on TipRanks | November 9, 2022

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights. “We continued to expand the clinical development of our lead program, evorpacept, during the third quarter of 2022, with the announc

Yahoo | November 8, 2022

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the Company will be presenting clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (“AML”) at the 64th American Society o

Yahoo | November 3, 2022

ALX Oncology Announces Upcoming Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in four upcoming investor conferences. Credit Suisse 31st Annual Healthcare ConferenceFormat: Formal presentationDate: Wednesday, November 9Time: 9:50 AM Pacific Time/ 12:50 PM Eastern TimeLocation: Rancho Palos Verdes, CAWeb

Yahoo | November 2, 2022

Read More 'ALXO' Stories Here

ALXO Price Returns

1-mo -16.13%
3-mo -21.99%
6-mo 56.37%
1-year -67.71%
3-year N/A
5-year N/A
YTD -50.63%
2021 -75.07%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6218 seconds.